SYNTHETIC METHYLMALONYL-COA MUTASE TRANSGENE FOR THE TREATMENT OF MUT CLASS METHYLMALONIC ACIDEMIA (MMA)
    9.
    发明申请
    SYNTHETIC METHYLMALONYL-COA MUTASE TRANSGENE FOR THE TREATMENT OF MUT CLASS METHYLMALONIC ACIDEMIA (MMA) 有权
    用于处理MAM类甲基马来酰亚胺(MMA)的合成甲基马来酰亚胺转移酶

    公开(公告)号:US20170067042A1

    公开(公告)日:2017-03-09

    申请号:US15070787

    申请日:2016-03-15

    CPC classification number: C12N9/90 A61K38/00 C12Y504/99002

    Abstract: Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).

    Abstract translation: 本文描述了编码人甲基丙二酰-CoA变位酶(synMUT)并在细胞培养和/或受试者中表现出增强表达的合成多核苷酸。 在肝特异性启动子(AAV2 / 8-HCR-hAAT-synMUT-RBG)的控制下编码synMUT的腺相关病毒(AAV)基因治疗载体成功地拯救了由甲基丙二酰辅酶A变位酶缺陷小鼠显示的新生儿致死表型 降低了处理动物中的循环甲基丙二酸水平,并导致体内synMUT转基因产物的长期肝表达,人甲基丙二酰辅酶A变位酶(MUT)。

Patent Agency Ranking